Master your fundamental research. Join 79,627 investors who trust our platform and content.
Save 54+ hours of fundamental research with free access to Stock Card.
We only ask your name and email address.
KEY POINTS
OVERALL MARKET
Positive Employment Report numbers boosted some of the indices to what was nearly a green stock market.
The market indices ended the day mixed with only the NASDAQ dropping slightly.
The DOW Jones hit a record high today, boosted by the positive Bureau of Labor Statistics' Employment report. 943,000 jobs were added to non-farm payrolls in July, a great indicator of economic growth. However, President Biden warned that despite the great numbers, the threat of the delta variant is still growing by the day. Nevertheless, investors continued to push the market higher. GET THE DAILY MARKET RECAP
Did you know you can get your Daily Market recap report on YouTube, listen to it on our Podcast, or get it in your inbox?
Watch it, Listen to it, Or, read it. Sign up for a free Stock Card account to get the report in your mailbox every day. WHATS UP?
Monster Beverage (MNST) stock jumps on great earnings, as Celsius (CELH) aims to become a player in the same space.
Monster Beverage Co. (MNST) is a leader in the energy drink industry. I noticed that its stock was up over 5% today after a positive earnings report. The company hit a record with net sales increasing by 33.6%, and earnings per share were also up 28.6%. It has maintained upward trends in sales and profitability, despite supply chain issues and the rising cost of aluminum, which management referenced in the earnings report.
The company has a distribution deal with Coca-Cola (KO), and several energy drinks brands. The benefits of its product variety and strategic partnerships are shown by the all-green ratings we see on the Operations section of its Stock Card. It also has no concerns over debt, with great earnings ratios compared to any short or long-term debt obligations. Monster's performance is good for its investors but is showing great signs for another stock's investors. Celsius (CELH) is another company growing in the energy drink and beverages space that has been a darling of the investment community on Twitter. The growth we have seen with Monster proves that there is still plenty of room left in the market for Celsius to grow. Looking at the company’s Stock Card, much like Monster, Celsius has a solid foundation for growth, with no debt worries. Sales growth is trending upwards strongly, and Earnings Per Share are solid. Scrolling further down to past investment returns, it appears you would be a happy camper if you had invested in this company during the past 10 years. Celsius is growing steadily and isn’t showing any signs of stopping. It also differentiates itself from many other energy drink brands by its no preservatives, vegan, soy, gluten, and sugar-free line of products. This is a great investment, hitting the sweet spot between the demand for energy drinks and healthy alternatives. I’m going to keep a close eye on it as I consider adding some shares to my portfolio. I know a few of the portfolio publishers and Stock Card partners already own and have picked Celsuis in the past. If you were a follower of their portfolios, you would have received a notification when they picked the stock. WHATS DOWN?
FireEye (FEYE) and Zynga (ZNGA) both dropped in price today after unimpressive earnings reports.
Cybersecurity company FireEye (FEYE) stock dropped today after an unimpressive second-quarter earnings report yesterday. The company acknowledged that the sale of FireEye Products for $1.2 Billion to Symphony Technology (STG) in June impacted revenue significantly. Despite the increasing need for cybersecurity in nearly every industry, the growth wasn't as impressive. If you are not impressed by FireEye like me, it's worth your time to take a look at the cybersecurity list of stocks on Stock Card by typing cybersecurity in the search bar.
The next loser of the day is Zynga (ZNGA), who forecasted a decrease in mobile gaming, and landed on Stock Card’s losers list today with an 18% drop. The mobile video game company Zynga released its earnings report yesterday, detailing a record cash flow, 11% higher than last year’s second quarter. During the conference call, the CEO admitted that sales had declined towards the end of the quarter as people got out of their houses. This is expected to impact future revenue, and the forecast was updated to reflect that. This is a trend we should be seeing from many entertainment and gaming companies as people go back to normal, and that may mean some market overreaction to your favorite stocks. So keep an eye on your entertainment stocks, and hold on tight! FEATURED PARTNER PORTFOLIO
Did you catch Brian Feroldi and Brian Stoffel’s livestream with Stock Card?
Folks, two of my favorite stock market analysts and diligent stock researchers, Brian Feroldi and Brian Stoffel, have joined the community of Stock Card portfolio publishers. Yesterday, both Brians hopped on a livestream to analyze a stock and highlight some useful features of Stock Card.
Their mission is to spread the knowledge people need for financial wellness. That mission lines up with our goals at Stock Card quite well! I highly recommend visiting the Stock Picks page and look up Brian Feroldi and Brian Stoffle and their portfolios live on our website. Brian Feroldi runs two: a Quality Checklist Portfolio and an interesting Anti-Portfolio, which consists of the stocks he reviews but doesn’t think quite stack up. Brian Stoffel also has two portfolios: the Fragile Portfolio and Anti-fragile Portfolio You can always find our partner investors’ portfolios by searching their name on the left-hand side of the Stock Picks page. Don't forget to follow these four new portfolios on Stock Card to get notified of their future additions. WANT TO RECEIVE THIS DAILY STOCK MARKET RECAP IN YOUR MAILBOX?
Sign up for a free account on Stock Card's website to get the daily market recap reports in your inbox:
KEY POINTS
OVERALL MARKET
The market indices ended today green as investors wait for July's Employment report.
The market indices ended the day in the green. The S&P reached a new record high today, despite a lack of big news to move the market. Investors are awaiting the Fed’s Employment report for July on Friday, which will impact the upcoming decisions on monetary policy. Analysts are torn on whether it will dip lower or skyrocket, with estimates ranging between 350,00 to 1.2 million new jobs created. However, today's new jobless claims report hit a pandemic-era low and that helped boost the market in anticipation of tomorrow's employment report. GET THE DAILY MARKET RECAP
Did you know you can get your Daily Market recap report on YouTube, listen to it on our Podcast, or get it in your inbox?
Watch it, Listen to it, Or, read it. Sign up for a free Stock Card account to get the report in your mailbox every day. WHAT'S UP?
Positive developments from EDIT and NTLA earnings pulled gene-editing stocks higher today.
Today I noticed multiple gene-editing stocks hitting the green on Stock Card’s winner’s list and my own portfolio. When there is positive news and developments in the field from clinical trials from one or two companies in the space, it pushes almost all stocks in that industry upwards with excitement. Today good news came from Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) that released earnings reports with positive developments in their R&D and trial results.
Editas Medicine (EDIT) announced its first pediatric and adult high-dose cohorts for its EDIT-101 BRILLIANCE trial in its earnings report. This is a CRISPR-technology treatment for an inherited disease in human eyes. Also, the company’s sickle cell disease trial is on track to have its first dose given this year. Investors reacted positively to this news, brushing off the disappointing financial numbers that came through the earnings report. From the company's Stock Card, we know it is unprofitable and the losses keep getting bigger. Intellia Therapeutics (NTLA) also brought good news to the table in its own earnings report. The company has been making progress with applying CRISPR therapy “in vivo,” or in other words, to living patients, not to a petri dish in a lab. Intellia announced that it now has a proof-of-concept for the technology. We covered some of this news as it broke, in a past episode. Generally, when it comes to biotech companies like EDIT and NTLA, being involved in clinical trials means limited to no revenue and profit. What matters is cash. Both companies have solid cash reserves which we can see in the Cash Availability section of their Stock Cards. I own shares of both, have added to them several times, and plan to hold them for now. One of the challenges with picking gene-editing stocks is the high volatility that comes with clinical trial news. Small good news can surge the stock high up, while small bad news can have the exact opposite effect. Meanwhile, the company is precisely the same company it was before the news. One way to deal with it is to focus on ETFs in the space. For example, take a look at ARKG, the genomic-focused ETF by ARK Invest on Stock Card. Its top 25 holdings include the majority of gene-editing stocks that you would want to have on your radar. Also, as usual, you can type in gene editing in the search bar and get the full list of gene-editing stocks to start your research. I'll leave a link to the gene-editing list of stocks in the show notes. WHAT'S DOWN?
Fiverr posted good earnings numbers, but the forecast for next quarter scared investors.
On the losers list, I noticed Fiverr (FVRR). The company released its earnings report late last night. Despite great numbers, the stock dropped immediately on open today and finished out the session with a 24% drop. According to the report, revenue grew 60% year-over-year as all metrics surpassed pre-pandemic growth levels. Active buyers grew 43% compared to this month last year, which was in the middle of the pandemic.
The stock dropped because of the company’s outlook for the rest of the year. The CEO cited people’s return to the outside world from lockdowns as a factor. Fiverr expects to see year-over-year revenue growth of 30-38% in the upcoming 3rd quarter, which is nearly half of this quarter’s results. What did investors expect? The drop is quite expected. What matters is the company's ability to keep growing from here and use the user base it acquired to engage and spend more on the platform. I own shares, and if the drop continues, I may be a buyer once again. FEATURED PARTNER PORTFOLIO
Did you catch today's live stream by Brian Feroldi and Brian Stoffel with Stock Card?
Before we wrap this up, you may have noticed the excitement in my voice today. That's because two of my favorite stock market analysts and diligent stock researchers, Brian Feroldi and Brian Stoffel joined the community of Stock Card portfolio publishers. Today, both Brians hopped on a Youtube livestream to analyze a stock and highlight some useful features of Stock Card.
Their mission is to spread the knowledge people need for financial wellness. That mission lines up with our goals at Stock Card quite well! I highly recommend visiting the Stock Picks page and look up Brian Feroldi and Brian Stoffle and their portfolios live on our website. Brian Feroldi runs two: a Quality Checklist Portfolio and an interesting Anti-Portfolio, which consists of the stocks he reviews but doesn’t think quite stack up. Brian Stoffel also has two portfolios: the Fragile Portfolio and Anti-fragile Portfolio. You can always find our partner investors’ portfolios by searching their name on the left-hand side of the Stock Picks page. Don't forget to follow these four new portfolios on Stock Card to get notified of their future additions. WANT TO RECEIVE THIS DAILY STOCK MARKET RECAP IN YOUR MAILBOX?
Sign up for a free account on Stock Card's website to get the daily market recap reports in your inbox:
KEY POINTS
OVERALL MARKET
The market indices ended today mixed after news of an underwhelming jobs report.
The market ended the day with mixed indices. Only the NASDAQ managed to make it into the green.
The job situation in America is getting better, but it has not been without its hiccups. The unsteady growth and the uncertainty that comes with it likely held the markets back today. For example, today’s ADP payroll report is up 330,000 jobs, which is positive, but still short of DOW Jones' estimate of 653,000. This is the smallest monthly growth since February. Lower than expected jobs-related numbers typically hurts the market, as it did today. GET THE DAILY MARKET RECAP
Did you know you can get your Daily Market recap report on YouTube, listen to it on our Podcast, or get it in your inbox?
Watch it, Listen to it, Or, read it. Sign up for a free Stock Card account to get the report in your mailbox every day. WHAT'S UP?
Investors wonder if there is an opportunity for significant growth once again as vaccine stocks begin to rise.
The winners' list on Stock Card today featured some big jumps in vaccine stocks. New monthly COVID cases are outpacing last year’s numbers, highlighting the need for more vaccine development and research.
Novavax Inc (NVAX) was the first company that caught my eye. Novavax stock shot up by over 18% today after announcing that the company had reached an agreement with the European Commission for the advance purchase of 200 million vaccine doses. The company is currently developing a protein-based vaccine that is showing promise in clinical trials. The European Commission stated that it wants to expand the vaccine portfolio available to citizens, which now includes seven different vaccines. The question we all ponder upon now is whether it's time to rebuy vaccine stocks. Let me share my story here. Last summer, I bought some Moderna (MRNA) stock when the stock got beaten down after the initial rise. You can see that in my Windmill portfolio, which is a portfolio with a small amount of money for things I'm experimenting with and don't necessarily want to own for a long time. I ended up selling at a loss because I realized I wasn't sure about the company and assumed I had missed the boat. The stock price is much higher than where I sold, and the story taught me two things: The risk with vaccine stocks is that you never know which one will lead the race. With vaccine stocks, you need to be both patient and lucky. One way to deal with such uncertainty is to invest in a vaccine ETF such as GERM. You can research it by typing “GERM” in the search bar on Stock Card and clicking on the suggested ETF. GERM is a passively managed fund focused on the treatment, testing, and advancement of vaccines. The ETF is hitting its 52-week high now, and market sentiment is quite up too. This tells you that vaccine stocks as a whole have a run-up, and if you are investing, you are betting on the continued excitement. You’ll need to be patient and lucky to turn a small amount of money into a lot. WHAT'S DOWN?
Cardlytics (CDLX) stock takes a steep fall after its earnings report.
Cardlytics (CDLX) stock is down over 27% today after yesterday’s underwhelming earnings report. The stock was also down double-digit yesterday, so it keeps showing up on Stock Card’s losers list.
Let's see why. Cardlytics is an advertising company that works closely with banks to deliver the most attractive deals it can to their customers. Cardlytics uses purchase data from retailers online and in stores to match promotions with customers already acquired by banks, increasing revenue from their current customer bases. This is a great business model that is surely worth it for these banks, but looking at the company’s Stock Card, I am not too convinced it's a good business model for Cardlytics itself. It's not profitable and it doesn't generate free cash flow. Sales growth has slowed down too. For example, in its latest earnings report, revenue was $58.9 million, an increase of 109% year-over-year, compared to $28.2 million in the second quarter of 2020, yet the results were still short of expectations held by investors and management alike. The CEO blamed supply chain issues and slow economic reopening for the miss. Scrolling further down, at 11% short interest, it appears many investors are betting against the stock. There is a significant amount of doubt in this company, and possibly for good reason. I don't know the company enough to say it's an opportunity to buy this dip. It seems there is not enough evidence to see whether the company can turn around its growth and start generating cash and profit. FEATURED PARTNER PORTFOLIO
Check out Wealthy Nurse Janee's portfolios, our featured investor and partner of the week.
Let's wrap up by stopping by Jane Clay's portfolios on Stock Card. Janee is the founder of Wealthy Nurse Janee, and is our featured investor of the week. Janee runs two portfolios on Stock Card: her Dividend and Value as well as her Higher Risk portfolio.
I'm so impressed by her return, but also by her superwoman powers. She is a nurse, as you can guess from her name, a mom, an avid investor, and she is quite active on TikTok. I'll leave a link to my conversation with Janee. I would highly recommend looking her up on search bar found on the Stock Picks page and following her portfolios to get notified when she adds new stocks to them. WANT TO RECEIVE THE DAILY STOCK MARKET RECAP IN YOUR MAILBOX?
Sign up for a free account on Stock Card's website to get the daily market recap reports in your inbox:
KEY POINTS
OVERALL MARKET
The market indices ended in the green today as the Treasury yield steadied.
All three market indices ended in the green today.
There wasn't a major story that could have moved the market. The Treasury yield, earnings reports, and the number of new COVID cases are the typical market forces that came into play today. On the positive side, the 10-year Treasury yield leveled out, and there were quite a few positive earnings reports. However, the news of the new COVID delta variant continues to worry investors. GET THE DAILY MARKET RECAP
Did you know you can get your Daily Market recap report on YouTube, listen to it on our Podcast, or get it in your inbox?
Watch it, Listen to it, Or, read it. Sign up for a free Stock Card account to get the report in your mailbox every day. WHAT'S UP?
SolarEdge Technologies (SEDG) managed to deliver great results on today’s earnings report despite supply chain issues.
On today’s list of winners on Stock Card, you’ll find SolarEdge Technologies (SEDG) up by 16%. While the company went through some supply chain issues, the CEO stated in today’s earnings report that the company had the foresight to see these difficulties and managed to turn even more profit.
SolarEdge beat forecasts for revenue and earnings per share with an increase in revenue from $331.9 to 480.1 million this quarter. Such a performance was cause for celebration, and investors welcomed the numbers by pushing the stock higher. Management also forecasts an increase to $520-540 million of revenue for the upcoming third quarter. This optimism attracted investors and gave it the push it needed to rise 16% by closing time. I own the stock, so I'm a happy camper. The reason I held the stock despite some volatility in the past is apparent on the company’s Stock Card. The solar power industry is growing rapidly, and the company is profitable with solid cash. Also, folks, before we head to the loser stock, I want to revisit a big story quickly. Robinhood (HOOD) stock had a rough IPO, as we discussed a few days ago. Today, however, the stock closed up over 24%, reaching a price of $46.80. This is a rebound from the low it hit of $33.25. The stock price jump seems to be the courtesy of the individual investors who are just warming up to the idea of being a Robinhood investor. CNBC says HOOD was the most traded stock on Fidelity. Because Robinhood has at least 25% of its share available for trading by individual investors, we should expect volatility. Also, it didn't hurt that Cathie Wood's funds started picking up shares as soon as the stock went public. It seems retail investors are pushing their favorite stock up. I genuinely want to know why Cathie is investing in HOOD, and why she is not concerned about its revenue sustainability. WHAT'S DOWN?
Tencent (TCEHY), Activision (ATVI), and NetEase (NTES) all took losses today as the Chinese government puts its sights on the video game industry.
On the losers' side, if you’ve been following the situation overseas, you’ll know that China is in the middle of quite the crackdown on some of its stocks, like we've seen in the education industry, which we covered earlier. Today, a new industry is taking up space on the Stock Card losers list. Video game companies in China and the U.S. took losses after the government heavily criticized the gaming industry over its effects on the younger generation.
Tencent (TCEHY) was one of the first companies to respond to the state’s remarks, announcing that it would be taking action to keep younger players from spending so much time on one of its popular games, Honor of Kings, and eventually more titles. This will damage its revenue stream from gaming, and the stock price reflected this by falling over 7% by the close. Tencent also holds a 5% stake in gaming giant Activision Blizzard (ATVI). This company has a large exposure to the Chinese gaming industry through popular titles such as Call of Duty, World of Warcraft, Overwatch, etc. This relationship caused Activision’s share price to drop by 3.5% today as well. NetEase (NTES) is a rival entertainment company in China, heavily involved in gaming as well. The government’s criticism of video games caused NetEase stock to slide almost 11.5% by the close. This is causing widespread losses, but one can assume that China won’t destroy its lucrative industries. I'm wondering if the recent volatility in China may mean a good opportunity to buy an index fund or ETF that tracks China's growth. It's hard to target exactly which company is your best bet for buying the dip, but if overall China is beaten down now, it may mean a good chance to pick up some China-focused ETFs. Type in China in the search bar, and China Fund ETF (CHN) or MS China A Shares (CAF) will appear. These may be worth watching if the situation begins to improve. I'm researching these for now. FEATURED PARTNER PORTFOLIO
Check out Wealthy Nurse Janee's portfolios, our featured investor and partner of the week.
Let's wrap up by stopping by Jane Clay's portfolios on Stock Card. Janee is the founder of Wealthy Nurse Janee, and is our featured investor of the week. Janee runs two portfolios on Stock Card: her Dividend & Value portfolio and her Higher Risk portfolio.
I'm so impressed by her return, but also by her superwoman powers. She is a nurse, as you can guess from her name, a mom, an avid investor, and she is quite active on TikTok. I'll leave a link to my conversation with Janee. I would highly recommend looking her up on the Stock Picks page and following her portfolios to get notified when she adds new stocks to her portfolio. WANT TO RECIEVE THE DAILY STOCK MARKET REPORT IN YOUR MAILBOX?
Sign up for a free account on Stock Card's website to get the daily market recap reports in your inbox:
KEY POINTS
OVERALL MARKET
Low 10-year Treasury yields and COVID fears hindered the market’s growth today.
The stock market ended with mixed indices today, if only barely. The S&P 500 and the Dow Jones took a fall, while the NASDAQ managed to stay just above in the green.
With the 10-year Treasury yield drop and the rising number of COVID cases, the market’s lukewarm start to the week isn't unexpected. But, let's talk about something else. Professor Galloway is one of the smart folks I like to follow. He sent out a chart today that grabbed my attention. He looked at the price-to-sales ratio of companies and their stock price return in one quarter to 5 years. The results are quite interesting. If you are the holder of a company with a price-to-sales ratio above 15, you would have lost money over 2-year, 3-year, 4-year, and 5-year periods. Of course, this is based on historical data between 1970 to 2020, and things can change. The conclusion is that a high price-to-sales ratio may indicate the market's over-excitement about the company. Also, as you may know, on Stock Card, you can click on the Fairly-priced stock section, go to valuation multiples, and get the stock's price-to-sales ratio. For example, Amazon's (AMZN) price-to-sale ratio is around 4.5, and Square's (SQ) price-to-sales ratio is 9.5. I found the analysis quite interesting. GET THE DAILY MARKET RECAP
Did you know you can get your Daily Market recap report on YouTube, listen to it on our Podcast, or get it in your inbox?
Watch it, Listen to it, Or, read it. Sign up for a free Stock Card account to get the report in your mailbox every day. WHAT'S UP?
Buy now, pay later stocks are rocketing today after Square (SQ) purchases Afterpay (AFTPF)
You can find Afterpay (AFTPF) on the winner’s list on Stock Card today, as share prices were up almost 30% by closing time. The company announced today that it is being acquired by Square. Square (SQ) also saw a jump in price, gaining over 10% by closing time. Afterpay is the pioneer of digital “buy now, pay later” programs for retailers. We discussed this model when a rumor began spreading that Apple (AAPL) was possibly going to enter the same space.
It seems Square is taking advantage of this lower price caused by Apple's rumors to grow its user base, expand its offerings and keep its users engaged. Square wants to be the preferred financial institution for the younger generation. That means gaining users and engaging them by all means necessary to compete with traditional banks, and even fight with big tech like Apple entering the financial space. To me, this is another confirmation and reason to invest in Square when you can. Taking a glance at the company’s Stock Card, it is killing it with sales growth and profitability. I own shares, and I’ll keep buying if I can. WHAT'S DOWN?
Square’s acquisition of Afterpay overshadows Global Payments' (GPN) positive earnings report.
As they say, one person's happiness is another's misery or something like that. Afterpay's good news turned out to be bad news for Global Payments Inc (GPN) who landed on Stock Card's losers list. The company provides payment processing for small and medium-sized businesses. It was expecting a great day after releasing its earnings report, detailing a 56% increase in Earnings Per Share thanks to its overseas partnerships and increased profitability. Afterpay’s acquisition news spooked investors, who are wary of the competition. The stock dropped by 11% today.
The good news is, Global Payments Stock Card is still looking great. It’s a 3-greener with a lot of growth opportunities and strong profitability. The company also generates free cash flow, and even before today's price drop, it was fairly priced. The attention to and growth in the European markets that the company references in its earnings report is one reason why this may be a dip worth buying. This is certainly an interesting company to pay attention to. FEATURED PARTNER PORTFOLIO
Check out Wealthy Nurse Janee's portfolios, our featured investor and partner of the week.
Okay, today, I want to introduce you to Janee Clay, founder of Wealthy Nurse Janee and the featured investor of the week. Janee runs two portfolios on Stock Card: her Dividend & Value portfolio, as well as her Higher Risk portfolio.
I'm so impressed by her return, but also by her superwoman powers. She is a nurse, as you can guess from her name, a mom, an avid investor, and she is quite active on TikTok. I'll leave a link to my conversation with Janee. I would highly recommend looking her up on the Stock Picks page and following her portfolios to get notified when she adds new stocks to her portfolio. WANT TO RECEIVE THIS DAILY STOCK MARKET RECAP IN YOUR MAILBOX?
Sign up for a free account on Stock Card's website to get the daily market recap reports in your inbox:
|
Master your fundamental research. Join 79,627 investors who trust our platform and content.
Save 54+ hours of fundamental
research with free access to Stock Card. Categories
All
Archives
March 2024
|